Cohance Lifesciences Ltd Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Consolidate Quarterly Results

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Net Sales

544.55

555.57

549.31

840.42

676.23

603.77

488.08

Other Operating Income

0.00

Total Operating income

544.55

555.57

549.31

840.42

676.23

603.77

488.08

Raw Material Cost

196.50

191.60

178.33

202.23

188.91

165.62

153.30

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

-37.59

-50.47

-30.19

97.79

-0.07

7.85

0.85

Employee Cost

118.68

126.72

133.32

138.53

111.32

102.07

95.89

Power Cost

0.00

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

171.61

166.77

155.84

172.65

138.70

122.86

112.94

Total Expenditure (Excl Depreciation)

449.20

434.62

437.30

611.20

438.86

398.40

362.98

Operating Profit (PBDIT) excl Other Income

95.35

120.95

112.01

229.22

237.37

205.37

125.10

Other Income

6.16

15.60

14.17

12.05

21.56

16.19

19.41

Operating Profit (PBDIT)

101.51

136.55

126.18

241.27

258.93

221.56

144.51

Interest

9.11

8.76

10.18

10.45

10.80

9.61

10.20

Exceptional Items

-4.86

0.00

-8.10

-15.78

0.00

Gross Profit (PBDT)

87.54

127.79

107.90

215.04

248.13

211.95

134.31

Depreciation

46.94

44.02

45.14

54.17

43.56

37.79

31.28

Profit Before Tax

40.60

83.77

62.76

160.87

204.57

174.16

103.03

Tax

11.58

17.38

16.36

43.72

51.09

35.92

27.66

Provisions and contingencies

0.00

Profit After Tax

29.02

66.39

46.40

117.15

153.48

138.24

75.37

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

29.02

66.39

46.40

117.15

153.48

138.24

75.37

Share in Profit of Associates

0.00

Minority Interest

-7.70

-7.69

-2.48

-3.28

0.41

-0.23

0.00

Other related items

0.00

Consolidated Net Profit

36.72

74.08

48.88

120.43

153.07

138.47

75.37

Equity Capital

38.26

25.46

Face Value

1.0

Reserves

0.00

Earnings per share (EPS)

0.96

1.94

1.28

4.73

6.01

5.44

2.96

Diluted Earnings per share

0.96

1.93

1.27

3.1

4.01

3.61

1.97

Operating Profit Margin (Excl OI)

17.51%

21.77%

20.39%

27.27%

35.1%

34.01%

25.63%

Gross Profit Margin

16.08%

23.0%

19.64%

25.59%

36.69%

35.1%

27.52%

PAT Margin

5.33%

11.95%

8.45%

13.94%

22.7%

22.9%

15.44%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Dec 2025 is -1.98% vs 1.14% in Sep 2025

Consolidate Net Profit

QoQ Growth in quarter ended Dec 2025 is -50.43% vs 51.55% in Sep 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Dec 2025 is -21.17% vs 7.98% in Sep 2025

Interest

QoQ Growth in quarter ended Dec 2025 is 4.00% vs -13.95% in Sep 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Dec 2025 has fallen from Sep 2025

Compare Quarterly Results Of Cohance Life With

Select Peers

Figures in Cr

Consolidate Quarterly Results

Change(INR)

Change(%)

Net Sales

544.55

277.77

266.78

96.04%

Other Operating Income

0.00

Total Operating income

544.55

277.77

266.78

96.04%

Raw Material Cost

196.50

66.59

129.91

195.09%

Purchase of Finished goods

0.00

20.44

-20.44

-100.00%

(Increase) / Decrease In Stocks

-37.59

-21.30

-16.29

-76.48%

Employee Cost

118.68

46.78

71.90

153.70%

Power Cost

0.00

28.44

-28.44

-100.00%

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

171.61

37.83

133.78

353.63%

Total Expenditure (Excl Depreciation)

449.20

178.78

270.42

151.26%

Operating Profit (PBDIT) excl Other Income

95.35

98.99

-3.64

-3.68%

Other Income

6.16

9.98

-3.82

-38.28%

Operating Profit (PBDIT)

101.51

108.97

-7.46

-6.85%

Interest

9.11

0.08

9.03

11,287.50%

Exceptional Items

-4.86

-3.28

-1.58

-48.17%

Gross Profit (PBDT)

87.54

105.61

-18.07

-17.11%

Depreciation

46.94

18.75

28.19

150.35%

Profit Before Tax

40.60

86.16

-45.56

-52.88%

Tax

11.58

22.51

-10.93

-48.56%

Provisions and contingencies

0.00

Profit After Tax

29.02

64.34

-35.32

-54.90%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

29.02

64.34

-35.32

-54.90%

Share in Profit of Associates

0.00

-0.70

0.70

100.00%

Minority Interest

-7.70

-0.84

-6.86

-816.67%

Other related items

0.00

Consolidated Net Profit

36.72

64.48

-27.76

-43.05%

Equity Capital

38.26

10.46

27.80

265.77%

Face Value

1.00

0.00

Reserves

0.00

Earnings per share (EPS)

0.96

6.16

-5.20

-84.42%

Diluted Earnings per share

0.96

6.08

-5.12

-84.21%

Operating Profit Margin (Excl OI)

17.51%

35.64%

0.00

-18.13%

Gross Profit Margin

16.08%

38.02%

0.00

-21.94%

PAT Margin

5.33%

22.91%

0.00

-17.58%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 544.55 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is -1.98% vs 1.14% in Sep 2025

YoY Growth in quarter ended Dec 2025 is -19.47% vs 207.63% in Dec 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit 36.72 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is -50.43% vs 51.55% in Sep 2025

YoY Growth in quarter ended Dec 2025 is -76.01% vs 227.42% in Dec 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 95.35 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is -21.17% vs 7.98% in Sep 2025

YoY Growth in quarter ended Dec 2025 is -59.83% vs 259.22% in Dec 2024

Quarterly - Interest

Interest 9.11 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is 4.00% vs -13.95% in Sep 2025

YoY Growth in quarter ended Dec 2025 is -15.65% vs 400.00% in Dec 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 17.51%

in Dec 2025

Figures in %

QoQ Growth in quarter ended Dec 2025 has fallen from Sep 2025

YoY Growth in quarter ended Dec 2025 has fallen from Dec 2024